Literature DB >> 23490160

Normal enhanced liver fibrosis (ELF) values in apparently healthy subjects undergoing a health check-up and in living liver donors in South Korea.

Eun Jin Yoo1, Beom Kyung Kim, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Chae Yoon Chon, Hyon-Suk Kim.   

Abstract

BACKGROUND: The enhanced liver fibrosis (ELF) value is a non-invasive serum marker used for assessing liver fibrosis in chronic liver disease. To use the ELF value for the purpose of screening the general population and selecting subpopulations at high risk, it is important to know the normal range of ELF values as a prerequisite. AIMS: We aimed to define the normal range of ELF values by recruiting apparently healthy subjects and investigating factors influencing ELF values in subjects with minimal fibrotic burden.
METHODS: ELF values were determined in a cohort of healthy subjects who underwent a health check-up and in healthy living liver donors who were screened for transplantation. None of subjects suffered from chronic heart disease, diabetes mellitus, metabolic syndrome, hepatitis B, hepatitis C, or human immunodeficiency virus infection, systemic autoimmune disease or liver dysfunction.
RESULTS: Among 183 subjects analyzed, the normal ELF 5th through 95th percentile range was 5.95-8.73. Body mass index (P = 0.014) and male gender (P = 0.015) showed significant positive correlations with ELF value, whereas age did not. In multivariate linear regression analysis, platelet count was identified as the only independent factor influencing the ELF value (β=-0.006, P = 0.016). When considering the difference in ELF values between genders, the normal range of men was defined to be 6.72-8.93, this was slightly higher than that of women, 5.69-8.67.
CONCLUSIONS: We identified the normal range of ELF values and found that it can be significantly influenced by platelet count even in the healthy population.
© 2013 John Wiley & Sons A/S.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23490160     DOI: 10.1111/liv.12136

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  Utility of the ELF Test for Detecting Steatohepatitis in Morbid Obese Patients with Suspicion of Nonalcoholic Fatty Liver Disease.

Authors:  Iria Cebreiros López; Florentina Guzmán Aroca; Maria Dolores Frutos Bernal; Juan Antonio Luján Mompeán; Águeda Bas Bernal; Antonio Miguel Hernández Martínez; Enrique Martínez Barba; Jose Antonio Noguera Velasco; Pascual Parilla Paricio
Journal:  Obes Surg       Date:  2017-09       Impact factor: 4.129

2.  Latent Class Analysis of Noninvasive Methods and Liver Biopsy in Chronic Hepatitis C: An Approach without a Gold Standard.

Authors:  Flavia F Fernandes; Hugo Perazzo; Luiz E Andrade; Alessandra Dellavance; Carlos Terra; Gustavo Pereira; João L Pereira; Frederico Campos; Maria L Ferraz; Renata M Perez
Journal:  Biomed Res Int       Date:  2017-09-13       Impact factor: 3.411

3.  Enhanced Liver Fibrosis Score: Is It Useful for Evaluation of Fibrosis Severity in Chronic Hepatitis C Infection?

Authors:  Manish Kumar; Roshan George; Venkatesh Vaithiyam; Puja Sakhuja; Amol S Dahale; Aman Dayal; Ashok Dalal; Ujjwal Sonika; Sanjeev Sachdeva; Ajay Kumar
Journal:  Cureus       Date:  2022-01-12

4.  The performance of enhanced liver fibrosis (ELF) test for the staging of liver fibrosis: a meta-analysis.

Authors:  Qingsong Xie; Xiaohu Zhou; Pengfei Huang; Jianfeng Wei; Weilin Wang; Shusen Zheng
Journal:  PLoS One       Date:  2014-04-15       Impact factor: 3.240

5.  Diagnosis of Liver Fibrosis With Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein (WFA-M2BP) Among Chronic Hepatitis B Patients.

Authors:  Dong Wook Jekarl; Hyunyu Choi; Seungok Lee; Jung Hyun Kwon; Sung Won Lee; Hein Yu; Myungshin Kim; Yonggoo Kim; Pil Soo Sung; Seung Kew Yoon
Journal:  Ann Lab Med       Date:  2018-07       Impact factor: 3.464

6.  The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease.

Authors:  Paul M Trembling; Sophia Apostolidou; Aleksandra Gentry-Maharaj; Julie Parkes; Andy Ryan; Sudeep Tanwar; Matthew Burnell; Scott Harris; Usha Menon; William M Rosenberg
Journal:  BMC Gastroenterol       Date:  2020-04-15       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.